Arcturus Therapeutics Holdings Inc. $ARCT Shares Purchased by Amova Asset Management Americas Inc.

Amova Asset Management Americas Inc. raised its holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 6.4% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,947,835 shares of the biotechnology company’s stock after purchasing an additional 117,632 shares during the period. Amova Asset Management Americas Inc. owned 7.17% of Arcturus Therapeutics worth $35,879,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of ARCT. AQR Capital Management LLC acquired a new position in shares of Arcturus Therapeutics during the 1st quarter worth approximately $128,000. Millennium Management LLC acquired a new position in shares of Arcturus Therapeutics in the first quarter worth $4,892,000. Goldman Sachs Group Inc. boosted its stake in shares of Arcturus Therapeutics by 9.1% during the first quarter. Goldman Sachs Group Inc. now owns 509,712 shares of the biotechnology company’s stock valued at $5,398,000 after acquiring an additional 42,636 shares during the last quarter. Acadian Asset Management LLC purchased a new stake in shares of Arcturus Therapeutics during the first quarter worth about $701,000. Finally, Strs Ohio purchased a new position in shares of Arcturus Therapeutics during the first quarter valued at approximately $89,000. 94.54% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Arcturus Therapeutics

Here are the key news stories impacting Arcturus Therapeutics this week:

• Positive Sentiment: Pipeline progress: Arcturus outlined the launch of a 12‑week Phase II cystic fibrosis (CF) trial and said it expects regulatory clarity for ARCT‑810 in 2026 — a near‑term catalyst if milestones and timelines hold. Arcturus outlines 12-week Phase II CF trial launch and expects regulatory clarity for ARCT-810 in 2026 Q4 and FY2025 results and pipeline progress
• Neutral Sentiment: Minor analyst tweak: Citigroup raised its price target from $7 to $8 but kept a “neutral” rating — a modest endorsement but not a strong near‑term buy signal. Citigroup raises ARCT price target to $8
• Neutral Sentiment: Reported short‑interest data in recent summaries appears erroneous (zero shares / NaN change) and is not a meaningful indicator of current positioning. No reliable short‑squeeze signal is evident from those entries.
• Negative Sentiment: Quarterly miss: ARCT reported Q4 EPS of ($1.03) vs. consensus ($0.92) and revenue of $7.2M vs. $14.32M expected — the revenue shortfall and wider loss are the main drivers of the pullback. ARCT reports Q4 loss, misses revenue estimates Market reaction and Q4 details
• Negative Sentiment: Analyst volatility: Piper Sandler cut its price target sharply from $72 to $25 (still “overweight”), increasing headline risk and uncertainty around valuation — a big downward revision that can weigh on sentiment despite the maintained rating. Piper Sandler lowers ARCT PT to $25
• Negative Sentiment: Market reaction: Coverage noted an immediate share drop after the weak revenue print; higher‑than‑average intraday volume suggests selling pressure as investors digest the miss. ARCT falls on weak quarterly revenue

Analyst Upgrades and Downgrades

Several analysts have commented on ARCT shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arcturus Therapeutics in a research note on Wednesday, January 21st. Citigroup increased their price objective on shares of Arcturus Therapeutics from $7.00 to $8.00 and gave the stock a “neutral” rating in a report on Wednesday. HC Wainwright decreased their target price on shares of Arcturus Therapeutics from $12.00 to $9.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 11th. Wall Street Zen lowered shares of Arcturus Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. Finally, Piper Sandler cut their price target on shares of Arcturus Therapeutics from $72.00 to $25.00 and set an “overweight” rating on the stock in a research note on Wednesday. Eight equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Arcturus Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $28.89.

Arcturus Therapeutics Stock Performance

Arcturus Therapeutics stock opened at $7.58 on Thursday. The firm has a market capitalization of $215.35 million, a PE ratio of -3.18 and a beta of 2.40. Arcturus Therapeutics Holdings Inc. has a one year low of $5.85 and a one year high of $24.17. The stock’s 50 day moving average price is $7.29 and its 200 day moving average price is $11.35.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its earnings results on Tuesday, March 3rd. The biotechnology company reported ($1.03) EPS for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.11). The firm had revenue of $7.20 million for the quarter, compared to analyst estimates of $14.32 million. Arcturus Therapeutics had a negative return on equity of 28.63% and a negative net margin of 80.19%. On average, analysts forecast that Arcturus Therapeutics Holdings Inc. will post -2.22 earnings per share for the current fiscal year.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.